ACADIA Pharmaceuticals Inc. (LON:0A4W)

ACADIA Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	226.45	-61.29	-215.98	-167.87	-281.58
Depreciation & Amortization	15.88	5.55	2.03	3.34	2.93
Loss (Gain) From Sale of Assets	-146.52	-	-	-	0.28
Asset Writedown & Restructuring Costs	-	-	-	-	44.28
Loss (Gain) From Sale of Investments	-9.3	-12.12	-6.28	0.08	2.47
Stock-Based Compensation	67.05	66.42	68.2	63.62	84.42
Change in Accounts Receivable	-0.47	-36.07	2.17	-16.12	-12.47
Change in Inventory	-49.55	-28.81	2.42	-4.21	-3.32
Change in Accounts Payable	-1.35	4.8	5.87	-1.62	1.27
Change in Other Net Operating Assets	55.53	78.22	27.54	-2.88	25.55
Operating Cash Flow	157.72	16.7	-114.04	-125.66	-136.17
Operating Cash Flow Growth	844.31%	-	-	-	-
Capital Expenditures	-0.52	-0.05	-	-1.12	-7.59
Sale of Property, Plant & Equipment	146.52	-	-	-	-
Sale (Purchase) of Intangibles	-	-40	-	-	-
Investment in Securities	-176.53	72.05	73.24	-69.98	200.1
Investing Cash Flow	-30.54	32	73.24	-71.1	192.51
Issuance of Common Stock	6.85	25.13	8.2	18.16	81
Financing Cash Flow	6.85	25.13	8.2	18.16	81
Foreign Exchange Rate Adjustments	-0.09	-0.02	0.01	0.01	-0.01
Net Cash Flow	133.93	73.81	-32.59	-178.59	137.33
Free Cash Flow	157.2	16.65	-114.04	-126.78	-143.75
Free Cash Flow Growth	844.01%	-	-	-	-
Free Cash Flow Margin	16.41%	2.29%	-22.05%	-26.19%	-32.54%
Free Cash Flow Per Share	0.94	0.10	-0.71	-0.79	-0.91
Cash Income Tax Paid	19.52	5.85	2.19	1.04	1.11
Levered Free Cash Flow	270.08	28.44	-34.96	-65.26	-59.7
Unlevered Free Cash Flow	270.08	28.44	-34.96	-65.26	-59.7
Change in Net Working Capital	-135	-42.38	-34.56	24.58	-6.65

Source: S&P Capital IQ. Standard template. Financial Sources.